Thursday, October 15, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· June 17, 2026

Defiance Melancarkan SPCQ: Dana Dagangan Bursa (ETF) Sasaran Harian 2X Singkat untuk SpaceX

View original at globenewswire.com
Defiance Melancarkan SPCQ: Dana Dagangan Bursa (ETF) Sasaran Harian 2X Singkat untuk SpaceX MIAMI, June 17, 2026 (GLOBE NEWSWIRE) -- Defiance ETFs hari ini mengumumkan pelancaran Defiance Daily Target 2X Short SpaceX ETF (SPCQ), sekali gus memperluas rangkaian ETF leveraj saham tunggal yang direka khas untuk pedagang a…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • SpaceX was founded in 2002 by Elon Musk and develops and operates launch vehicles for commercial, government and defense customers, as well as providing satellite-based broadband services via the Starlink network.

    60% confidence
  • SpaceX may fail to meet publicly announced expectations regarding its business, launch operations, satellite deployment or commercial growth initiatives, which could cause the value of the underlying security to decline.

    60% confidence
  • SpaceX is a key participant in the commercial space industry, contributing to the expansion of global satellite communications and orbital launch capabilities.

    60% confidence
  • For recently listed companies, derivative instruments such as swaps and options may be limited, illiquid, expensive or unavailable, particularly shortly after an IPO or during periods of significant market uncertainty.

    60% confidence
  • Daily rebalancing of SPCQ is expected to result in a high portfolio turnover rate, which may increase transaction costs and potentially result in higher taxable distributions to shareholders.

    60% confidence
  • SpaceX's value may be significantly affected by Elon Musk's actions, decisions, and public statements. Public perception of his leadership or involvement in other ventures could influence investor sentiment and the performance of the underlying security.

    60% confidence
  • SPCQ seeks daily investment results, before fees and expenses, of -2 times (-200%) the daily percentage change in the price of SpaceX (NASDAQ: SPCX) stock. The fund does not seek to achieve its stated investment objective over any period other than a single trading day.

    60% confidence
  • SPCQ enters into swap agreements and options contracts based on the price of SpaceX stock (NASDAQ: SPCX) as part of its inverse investment strategy, exposing the fund to counterparty risk.

    60% confidence
  • SPCQ is a newly established investment management company with limited operating history, and therefore there is limited performance history for investors to use as a basis for evaluation.

    60% confidence
  • For periods longer than one trading day, the fund's performance will be the result of compounded daily returns, which will likely differ materially from -200% of SpaceX's return over the same period. Investors may lose their entire investment in a single trading day.

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com